文献速递临床生化临床免疫

Lumipulse自动化平台检测阿尔茨海默病血液生物标志物:年龄效应与临床价值解读

Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation.
PubMed 文献 · Clin Chim Acta · 2024-10-22

该横断面研究在80例认知障碍患者和55例认知正常者中,用Lumipulse全自动化学发光平台检测血与脑脊液的NFL、pTau181、Aβ1-42和Aβ1-40。血NFL鉴别神经退行性疾病的阈值随年龄变化,50-65岁为19 pg/mL,>65岁为33 pg/mL;AD最佳界定为Aβ1-42/1-40比值<0.079且pTau181>1 pg/mL。所有标志物血与脑脊液强相关,但仅血Aβ比值与脑脊液检测对AD诊断等效。

要点

  • 血NFL鉴别神经退行性疾病的阈值随年龄变化:50-65岁19 pg/mL,>65岁33 pg/mL。
  • AD最佳血液界定标准为Aβ1-42/1-40比值<0.079且pTau181>1 pg/mL。
  • 仅血Aβ比值与脑脊液检测对AD诊断等效,其他标志物虽强相关但不等效。

核心结论

  • 血NFL鉴别神经退行性疾病的阈值随年龄变化,50-65岁为19 pg/mL,>65岁为33 pg/mL。
  • AD最佳血液界定为Aβ1-42/1-40比值<0.079且pTau181>1 pg/mL。
  • 所有标志物血与脑脊液强相关,但仅血Aβ比值与脑脊液检测对AD诊断等效。

研究设计与样本

  • 横断面研究,纳入80例认知障碍患者和55例认知正常者。
  • 用Lumipulse全自动化学发光平台检测血和脑脊液的NFL、pTau181、Aβ1-42和Aβ1-40。
  • 用ROC曲线分析计算临床切点,并进行血与脑脊液检测的头对头比较。

主要发现

  • 血NFL鉴别神经退行性疾病与对照的最佳阈值随年龄变化:50-65岁为19 pg/mL,>65岁为33 pg/mL。
  • AD最佳血液界定为Aβ1-42/1-40比值<0.079且pTau181>1 pg/mL。
  • 所有标志物血与脑脊液强相关,但仅血Aβ比值与脑脊液检测对AD诊断等效。

关键数值与推荐

  • 血NFL鉴别神经退行性疾病阈值:50-65岁19 pg/mL,>65岁33 pg/mL。
  • AD血液界定:Aβ1-42/1-40比值<0.079且pTau181>1 pg/mL。

临床怎么用

  • 血NFL切点需按年龄分层应用:50-65岁用19 pg/mL,>65岁用33 pg/mL。
  • 血Aβ1-42/1-40比值<0.079且pTau181>1 pg/mL可用于界定AD。
  • 血Aβ比值与脑脊液检测对AD诊断等效,其他血标志物不能替代脑脊液检测。

局限性

  • 需考虑具体使用场景来定义神经退行性疾病血液标志物的切点。
  • 未来需建立每种AD血液标志物的参考物质以改进临床切点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advances in analytical methods have recently paved the way to Alzheimer's disease (AD) biomarkers testing in blood along with the more established CSF testing. To ensure a forthcoming application of this low-invasive diagnostic that might allow to recognize early onset of dementia, appropriate pathological cut-points need to be defined. METHODS: In this cross-sectional study we measured blood and CSF neurofilament light chain (NFL), phosphorylated tau (pTau 181), Amyloid-β1-42 (AB 1-42) and Amyloid-β1-40 (AB 1-40) on a fully automated chemiluminescent platform (Lumipulse, Fujirebio) in 80 cognitively impaired patients and 55 cognitively unimpaired subjects. Clinical cut points were calculated with receiver-operator characteristic (ROC) curve analysis and a head-to-head comparison of blood and CSF testing was performed. RESULTS: Blood NFL best discriminant thresholds to distinguish neurodegenerative diseases from controls varied age-dependently, being 19 and 33 pg/mL in subjects 50-65 years and > 65 years respectively. AD was best framed by AB 1-42/1-40 ratio < 0.079 and ptau181 > 1 pg/mL. Though a strong correlation for all biomarkers, only blood AB ratio was equal to CSF testing for AD diagnosis. CONCLUSIONS: The specific context of use might be considered to define the cut-offs of blood biomarkers of neurodegenerative diseases. Future efforts towards reference materials for each AD blood biomarker will improve clinical cut-offs.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Musso G, Gabelli C, Puthenparampil M, et al. Blood biomarkers for Alzheimer's disease with the Lumipulse automated platform: Age-effect and clinical value interpretation. Clin Chim Acta. 2024. PMID: 39442787. doi:10.1016/j.cca.2024.120014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。